In this webinar, Dr, Amaravadi:
- Provides a critical assessment of autophagy, tumor resistance and survival
- Discusses autophagy inhibition with HCQ, an antimalarial drug
- Introduces a new and potent autophagy inhibitor, Lys05
- Provides insight into targeting the lysosome in cancer and other diseases and how mechanism-based targeting may lead to a reduction in toxicities and side-effects
Dr. Amaravadi is the Cancer Therapeutics Program Co-Leader at the Abramson Cancer Center where his research centers on understanding the role of autophagy inhibition in cancer therapy. He has done fascinating research and has overseen clinical trials looking at autophagy inhibition as a treatment for solid tumors, multiple myeloma, and melanoma.